Innate Pharma S.a.s.

University of Genoa

Novo Nordisk A/s

Innate Pharma, S.a.

Novo Nordisk-a/s Novo Alle

Innate Pharma

Universita Di Genova

Mariella Della Chiesa

Alessandro Moretta

Pascale Andre

Peter Andreas Nicolai Reumert Wagtmann

Laurent Gauthier

Kristian Kjaergaard

Stefan Zahn

Anders Svensson

Ivan Svendsen

Francois Romagne

Soren Berg Padkjaer

Matthias Thorolfsson

Michael Wilken

Peter Andreas Wagtmann

Søren Berg Padkær

Pieter Spee

Francois Romagné

Milchael Wilken

Matthias Thórólfsson

Petrus Johannes Loius Spee

Søren Berg Padkjær

Pieter Johannes Louis Spee

Soren Berg Padkaer

Laurant Gauthier

Søren Berg Padkaer

Soeren Berg Padkaer

Soeren Berg Padkjaer

Allessandro Moretta

François Romagne

The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK call cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.

Compositions and methods for regulating NK cell activity

The present invention relates to novel antibody compositions for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.

PAN-KIR2DL NK-receptor antibodies and their use in diagnostics and therapy

Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Human anti-KIR antibodies

The present invention relates to a method of producing an antibody that cross-reacts with multiple KIR2DL polypeptides and neutralizes the inhibitory activity of such polypeptides.

Nucleic acids encoding human anti-kir antibodies

Growing community of inventors

Genoa, Italy

Mariella Della Chiesa